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Cancer survivors experience high levels of distress, whether 
after receiving a cancer diagnosis or during or following 
major cancer treatment, such as radiation, chemotherapy, and 
surgery. In many cancer survivors, posttreatment distress can 
be accompanied by a host of negative psychological states, 
including depression, despair, anxiety, posttraumatic stress 
symptoms, and fear of cancer recurrence, as well as sleep dis-
turbance.1-3 Sleep disturbance is a significant health problem 
in general, and is particularly so in cancer survivors, because 
of the role it may play in contributing to cancer occurrence 
and progression.4 Developing effective treatments to improve 
sleep might also help reduce distress and associated emotional 
states and generally improve the lives of cancer survivors. 
Since many cancer survivors are interested in nonpharmaco-
logical interventions to help deal with sleep problems and co-
occurring conditions,5 it is important to assess how effective 
these nonpharmacological interventions are in improving the 
lives of cancer survivors. Besides the use of validated 
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Abstract
Cancer survivors experience high levels of distress, associated with a host of negative psychological states, including 
anxiety, depression, and fear of recurrence, which often lead to sleep problems and reduction in quality of life (QOL) 
and well-being. As a neuropeptide hormone associated with affiliation, calmness, and well-being, oxytocin may be a useful 
biological measure of changes in health outcomes in cancer survivors. In this exploratory study, which comprised a subset 
of participants from a larger study, we evaluated (a) the feasibility and reliability of salivary oxytocin (sOT) levels in cancer 
survivors and (b) the effects of 2 sleep-focused mind–body interventions, mind–body bridging (MBB) and mindfulness 
meditation (MM), compared with a sleep hygiene education (SHE) control, on changes in sOT levels in 30 cancer survivors 
with self-reported sleep disturbance. Interventions were conducted in 3 sessions, once per week for 3 weeks. Saliva 
samples were collected at baseline, postintervention (~1 week after the last session), and at the 2-month follow-up. In 
this cancer survivor group, we found that intra-individual sOT levels were fairly stable across the 3 time points, of about 
3 months’ duration, and mean baseline sOT levels did not differ between females and males and were not correlated with 
age. Correlations between baseline sOT and self-report measures were weak; however, several of these relationships 
were in the predicted direction, in which sOT levels were negatively associated with sleep problems and depression and 
positively associated with cancer-related QOL and well-being. Regarding intervention effects on sOT, baseline-subtracted 
sOT levels were significantly larger at postintervention in the MBB group as compared with those in SHE. In this sample of 
cancer survivors assessed for sOT, at postintervention, greater reductions in sleep problems were noted for MBB and MM 
compared with that of SHE, and increases in mindfulness and self-compassion were observed in the MBB group compared 
with those in SHE. The findings in this exploratory study suggest that sOT may be a reliable biological measure over time 
that may provide insight into the effects of mind–body interventions on health outcomes in cancer survivors.
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self-reported outcome measures, biological measures are 
increasingly used to evaluate the efficacy of these interven-
tions and to elucidate potential mechanisms whereby these 
interventions might improve health outcomes in cancer survi-
vors.6 Understanding physiological mechanisms involved in 
improving health, quality of life (QOL), and well-being in 
cancer survivors is especially important, since biomarkers 
used to evaluate the efficacy of psychosocial interventions 
may themselves be implicated in cancer disease processes. 
For example, while the stress hormone cortisol, a glucocorti-
coid, has provided some insight into the impact of psychoso-
cial interventions in ameliorating stress in cancer survivors,7 
glucocorticoids are increasingly studied to understand their 
influences in cancer occurrence and progression.8 Since stress 
hormones exert anti-inflammatory effects, and impaired 
immune function is involved in tumor formation potentially 
leading to metastases,9 targeting stress hormones might lead 
to beneficial outcomes in cancer prognosis. Additionally, it 
would be helpful to identify other biological measures that 
might provide mechanistic evidence of improved well-being 
and QOL in cancer survivors following psychosocial inter-
ventions, as well as the biological measures having a more 
direct relevance to, and involvement in, cancer. One candidate 
biomarker receiving much attention in relation to improved 
psychosocial states is the hormone oxytocin (OT), which may 
be particularly pertinent to study in cancer survivors, given 
their high levels of distress, negative affect, and other psycho-
logical health conditions, as well as sleep disturbance. 
Furthermore, OT may be involved in the regulation of cancer 
cells and may also be implicated in influencing sleep patterns. 
In view of the potential role of OT in cancer and sleep, and the 
lack of studies examining peripheral, endogenous OT in can-
cer survivors, the aims of this study were to investigate the 
suitability and applicability of using salivary OT (sOT) to 
determine (a) the impact of mind–body interventions target-
ing sleep on sOT release, (b) the feasibility and reliability of 
measuring sOT in a clinical study, and (c) associations 
between sOT and psychosocial variables. Overall, these aims 
served to evaluate the reliability and suitability of sOT as a 
biological indicator of positive health outcomes following 
psychosocial interventions in cancer survivors.
Oxytocin is a neuropeptide hormone produced in the 
hypothalamus, whose release activates a variety of brain 
regions leading to multiple physiological and behavioral 
effects. Oxytocin has been implicated in birth (labor), lacta-
tion, maternal behavior, parental care, social bonding, affili-
ation, and well-being.10-12 In recent human studies, OT has 
been shown to be associated with social bonding,13-16 
trust,17-20 altruism and generosity,21 parochial altruism,22 
cooperation,23 empathy,24,25 and well-being.26 These find-
ings have been established in studies measuring endoge-
nous (circulating) as well as exogenously administered 
intranasal OT.27 The various functions attributed to OT have 
led to increased interest in understanding the role of OT as 
a mediator of prosocial behaviors, with implications for 
promoting health and well-being in humans.
Although OT was originally recognized for its physio-
logical functions, specifically its role in reproduction, and 
notably parturition and lactation, it has also been identified 
in other peripheral tissues such as heart, kidney, pancreas, 
and thymus, where it mediates its effects via OT receptors 
located in these organs.28 More recently, OT receptors were 
identified in neoplastic tissues,29 in which OT might play a 
regulatory role in tumor growth, since in vitro studies dem-
onstrated that OT inhibited the proliferation of breast, endo-
metrial, glial and neural, and bone neoplastic cell lines, and 
an in vivo study showed that OT inhibited breast tumor 
growth in mice that were injected with a mammary tumor 
and treated with subcutaneous pulsatile administration of 
OT (reviewed in Cassoni et al30). In contrast, OT can also 
stimulate tumor growth, as identified in other human cho-
riocarcinoma cell lines, or endothelial-derived sarcomatous 
cell lines from Kaposi’s sacrcoma; this stimulatory effect 
has been also noted in normal nonneoplastic endothelial 
cells in vitro (see Cassoni et al30). Further studies are neces-
sary to explicate the regulatory processes of OT in cancer 
cells to further understand potential clinical effects of OT in 
cancer.
Despite some understanding of the role of OT in cancer 
cells, there is virtually no information available about circu-
lating (plasma) or salivary OT in cancer patients at any 
stage of cancer diagnosis, or in cancer survivors. As such, 
very little is known regarding relationships between OT and 
clinical variables of cancer or prognosis. Obtaining this 
information is crucial if OT levels in cancer survivors could 
provide some understanding of whether a cancer patient or 
survivor has a potentially worsened or improved prognosis. 
Knowing what constitutes “healthy” OT levels in cancer 
survivors could additionally provide important information 
for inferences about a cancer survivor’s prognosis. Since 
OT has shown to be involved in the regulation of prosocial 
behaviors and can moderate relationships between psycho-
social variables,31,32 characterizing fluctuations in OT based 
on changes in these other variables might provide an under-
standing of potential mechanisms whereby OT might exert 
its effects to improve cancer survivors’ psychological states. 
Furthermore, if OT could be positively regulated by psy-
chosocial or mind–body interventions, which would elicit 
increased well-being and decreased stress and anxiety, this 
finding might provide some rationale for developing inter-
ventions to enhance these psychosocial states, specifically 
in terms of enhancing their well-being and QOL, which 
might have implications for improving the prognosis of 
cancer survivors.
The involvement of psychosocial factors in cancer occur-
rence and progression is an active area of interest.8 Psychosocial 
factors can interact with tumor cells via systemic and molecu-
lar communication involving the neuroendocrine system.33 
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One psychosocial factor known to be implicated in cancer is 
social support, which might be a significant predictor of cancer 
progression.34 Social support is positively correlated with 
endogenous OT levels,14 and OT can enhance the effects of 
social support to improve health outcomes, related to stress,35 
immune function,31 and sleep.32 Thus, it is possible that OT 
could also mediate the relationship between social support and 
cancer prognosis and might also impact sleep performance.
The role of OT in sleep has not been extensively evalu-
ated in humans, and one study on the topic indicated that 
OT levels are not altered by sleep or stage of sleep.36 
However, OT might indirectly influence sleep patterns by 
its anxiolytic effects, and its ability to facilitate reduced 
stress responses, mediated through its effects on the hypo-
thalamic–pituitary–adrenal (HPA) axis.37,38 In rodents, OT 
in the brain can regulate the HPA axis by inhibiting both 
basal and stress-induced adrenocorticotropin hormone 
(ACTH), and consequently glucocorticoid (corticosterone) 
release, as well as the ACTH hypothalamic releasing hor-
mone, corticotropin releasing hormone (CRH).39,40 Among 
the many significant functions of the hypothalamus is its 
involvement in sleep–wake activities38; both the HPA axis 
and CRH influence sleep patterns in animals and humans.39,40 
Since OT is produced in the paraventricular nucleus (PVN) 
of the hypothalamus, which is involved in regulating sleep 
and arousal, OT may indirectly influence sleep–wake 
behavior through its actions on the HPA axis and CRH.38 
Alternatively, OT may be more directly implicated in sleep 
as shown in rodents, in which central (brain) OT adminis-
tration led to wakefulness, while blocking OT release with 
an OT receptor antagonist resulted in reductions in non–
rapid eye movement and pre–rapid eye movement sleep, 
suggesting an hypnotic effect of OT.41 Lancel et al41 postu-
lated a dual mechanism of physiological action of central 
oxytocin on sleep: under basal conditions, endogenous oxy-
tocin may stimulate physiological sleep, whereas under 
conditions of stress, related to increased levels of brain oxy-
tocin, OT may contribute to behavioral arousal and/or 
impaired sleep quality. Following this thread, OT may exert 
similar effects on sleep in humans, especially those exhibit-
ing chronic stress and sleep disturbance. Given that OT may 
influence sleep and other behavioral variables depending on 
its concentration, OT might account for differences in 
health outcomes, including sleep. For example, in low-
income minority women living with HIV, perceived stress 
was associated with better immune status, and friendships 
with improved sleep, in those with high, but not low, OT 
levels.31,32
So how might OT elicit these beneficial effects? Given 
OT’s role in strengthening affiliations and promoting social 
interactions, endogenous OT has been hypothesized to pro-
mote relaxation and reduce feelings of vulnerability, and to 
engender feelings of increased safety and well-being as 
well as its ability to confer a sense of connectedness.42 
Endogenous OT can also act as a buffer against stressful 
situations, an “antistress system,” to inhibit negative psy-
chological states, including stressful, anxious, or fearful 
behaviors and feelings.37 As indicated earlier, OT is hypoth-
esized to exert these anxiolytic effects by reducing auto-
nomic nervous system reactivity via the HPA axis and 
cardiovascular stress system to lower heart rate and return 
blood pressure to normal levels.37,43 These stress- and anxi-
ety-reducing features of OT make it a promising hormone 
to examine in clinical populations such as cancer survivors, 
who are particularly prone to high levels of stress.
It would be helpful to identify therapeutic interventions 
that target the oxytocinergic system to assist in reducing 
negative psychological states and improving psychosocial 
factors to foster longer-term health benefits.11 Therapies 
especially incorporating strong affiliative and tactile com-
ponents could harness the beneficial effects of OT, as indi-
cated above. Indeed, gentle or warm touch and massage 
have been shown to instill feelings of relaxation, calmness, 
well-being, and connectedness, and reduce stress and anxi-
ety,37 and may be associated with increases in endogenous 
OT levels.37,44-48 Thus, touch therapies, acting in part by 
triggering OT release, may help reduce distress, by induc-
ing feelings of calmness, relaxation, and well-being in clini-
cal populations, including cancer survivors.
Another group of healing modalities effective in reduc-
ing stress and negative psychological states are mind–body 
interventions (MBIs) such as mindfulness-based stress 
reduction (MBSR)49 and mindfulness-based cognitive ther-
apy (MBCT),50,51 as well as a more recent addition, mind–
body bridging (MBB).52 MBIs have produced benefits in 
several clinical and healthy populations, including cancer 
survivors, and MBIs have been shown to be associated 
with declines in stress, depression, sleep disturbance, and 
increases in well-being and QOL.53-57 The effects of MBIs 
in treating sleep disturbance in cancer survivors is particu-
larly relevant, since many survivors experience poor sleep, 
which is associated with stress, anxiety, depression, 
fatigue,1 and fear of cancer recurrence.2 Thus, MBIs target-
ing stress and co-occurring conditions and reducing mental 
health problems can help improve sleep, as has been docu-
mented in cancer survivors in a number of studies.5,58-61 
Given the positive influences of MBIs on health outcomes, 
these improvements may also facilitate OT release, with 
positive health outcomes, as indicated previously. Thus, 
MBIs improving psychological states and influencing OT 
release could have potentially long-term benefits in cancer 
survivors.
In this exploratory and feasibility study, which analyzed a 
subset of participants from the main study,61 we evaluated 
the effects of 2 sleep-focused mind–body therapies (MBB 
and MM) on sOT levels in cancer survivors with self-
reported sleep disturbance. The data in the present study are 
drawn from the larger main study investigating the effects of 
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mind–body therapies on sleep disturbance and co-occurring 
symptoms in cancer survivors. Results of the main study 
indicated that the mind–body therapies were associated with 
reduced sleep disturbance and depression, as well as 
increased well-being, mindfulness, and self-compassion.61 
We hypothesized that these mind–body therapies would be 
associated with increases in sOT levels to a greater extent 
than would the sleep hygiene control, concomitant with 
improved sleep and co-occurring symptoms.
Methods
Participants
Details of the methodological aspects of this study have 
been presented in the main study61 and are provided here 
briefly. Participants were a subset of the main study, com-
prising 30 cancer survivors, and including 21 females and 9 
males, 29 to 74 years old, recruited primarily from various 
cancer hospitals and oncologists in private practice and a 
nonprofit cancer support center.
Inclusion Criteria. To be eligible, participants had completed 
active cancer treatment (surgery, chemotherapy, or radia-
tion) at least 3 months prior to the start of the first interven-
tion session. Cancer survivors were included if they 
exhibited self-reported sleep disturbance, as measured by a 
validated sleep questionnaire (Medical Outcomes Study 
Sleep Scale [MOS-SS]),62 with a score of 35 or greater on a 
composite summary subscale, the Sleep Problems Index II 
subscale (SPI-II). Individuals were excluded if they were 
not in remission or had metastatic disease, as was deter-
mined by their oncologist. They were also excluded if they 
displayed any serious mental health issues and had been 
previously exposed to MBB, MM, MBSR, or MCBT. The 
University of Utah Institutional Review Board approved the 
study protocol.
Study Design
In this prospective randomized-controlled study, we inves-
tigated the effects of sleep-focused mind–body interven-
tions, MBB and MM, compared with a sleep hygiene 
education control (SHE), on sOT levels, in this subset of 
cancer survivor participants from the main study,61 who had 
provided saliva samples for sOT evaluation. We addition-
ally assessed this subset sample for sleep disturbance, and 
other validated self-report questionnaires, including per-
ceived stress, depression, cancer-related QOL, well-being, 
mindfulness, and self-compassion, to determine if the 
results obtained in this subset were consistent with those 
obtained in the main study, as well as to examine potential 
associations between sOT levels and sleep, and psychologi-
cal states.
Study Procedures
Cancer survivors completed a screening questionnaire 
about their sleep patterns, demographics, cancer history 
(type of cancer and treatment), medical history, and medi-
cations/supplements used. If they were provisionally eli-
gible, the study team contacted their health care provider 
(with the participant’s signed consent) to verify that they 
were mentally competent and their cancer treatment status 
did not preclude participation in the study. Participants 
agreed to participate in the study by signing an informed 
consent form.
Following enrollment, participants were randomly 
assigned to one of the mind–body interventions or sleep 
education control. Each intervention comprised 3 sessions, 
conducted over 3 consecutive weeks and lasting approxi-
mately 2 hours each session. Saliva samples were collected 
at pre-intervention (baseline; Pre), postintervention (1 week 
after the third and final session, Post), and follow-up (2 
months posttreatment), and the self-report measures were 
collected at the same time points.
Interventions
Sleep Hygiene Education (Control). The instructor advised 
participants about using sleep hygiene approaches to deal 
with their cancer-related sleep issues. Each week, various 
sleep topics were discussed, including (a) possible causes 
of sleep disturbance, such as some medications, distress, 
anxiety, depression, or pain; (b) worries, concerns, and 
questions about sleep disturbance; (c) tips for getting a bet-
ter night’s sleep, such as diet, exercise, supportive care; (d) 
preparing for sleep; (e) tips on behaviors that could nega-
tively influence sleep quality; and (f) side-effects of sleep 
medications. After the various topics were presented, the 
group discussed their sleep issues related to their cancer 
experiences. Participants were encouraged to practice SHE 
recommendations on a daily basis. SHE was conducted by 
a licensed clinical social worker with experience in working 
with cancer survivors.
Mindfulness Meditation Program. Mindfulness meditation 
was an adaptation of Mindfulness-Based Stress Reduction 
(MBSR),49 which teaches awareness and mindfulness skills, 
including basic meditation practice and yoga. MBSR pro-
vides individuals with experiential tools and mindfulness 
techniques that help them observe their thoughts, emotions, 
and physical sensations and become more aware of the pres-
ent moment to deal with stressful events in their lives. MBSR 
has been shown to reduce stress, sleep disturbance, and other 
behavioral problems and has been tested in both healthy sub-
jects and those with clinical illnesses, including cancer sur-
vivors (for a meta-analysis review, see Grossman et al63). 
MBSR for sleep disturbance employs a 6-week-long 
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format,64,65 which is twice as long as the MM program 
implemented in the present study. While the 3-week MM 
program in the present study was not intended to cover all 
the elements included in the standard MBSR program, the 
specific goal of MM was to focus on and teach mindfulness 
meditation (eg, sitting, walking, and body scan). The MM 
course included fundamental mindfulness meditation skills 
(breath awareness, awareness of thoughts and emotions), 
body scans, walking meditation, and forgiveness meditation. 
After learning basic techniques, later sessions focused on 
ways in which participants implemented and integrated 
mindfulness into their daily lives. Participants also used a 
writing exercise to express a cancer-related concern that was 
stressful, with a focus on including emotional content and 
expressing themselves as fully as possible. The writing exer-
cise was included in MM to help participants become more 
aware of their thoughts, feelings, and emotions through their 
writings. Previous research indicates that expressive writing 
may help cancer survivors reduce their distress and fear of 
cancer recurrence, and in doing so, improve their psycho-
logical and physical health, including sleep disturbance 
related to cancer.66 Handouts for the course included MBSR 
CDs for mindfulness meditation, a copy of the book, Full 
Catastrophe Living,49 and a printout of “The practice of 
mindfulness” taken from the book, and stress reduction tips. 
MM was conducted by a licensed clinical social worker cer-
tified in MBSR.
Mind–Body Bridging Program. Mind–body bridging is a mind–
body intervention useful for a wide range of mental and 
physical health problems.52 MBB teaches mindfulness and 
awareness skills to help individuals recognize and become 
aware of potentially dysfunctional mental and bodily states, 
as indicated by ruminative thoughts and decreases in aware-
ness, and body tension, which could lead to potentially nega-
tive health outcomes. MBB provides experiential exercises 
in which individuals are taught to pay attention to sights, 
sounds, and sensations to calm their minds and relax their 
bodies. They are also taught “mapping” exercises, which 
may help reveal specific types of thought patterns, known as 
“requirements,” which are expectations about how people 
and the world should be at a particular moment. Examples of 
requirements are, “I should cope with my cancer more effec-
tively” and “I should not have any cancer symptoms.” 
Requirements can elicit negative feelings and emotions, 
which may contribute to distress, fear, anxiety, and worry, in 
the context of the cancer experience. Over time, require-
ments that are unmet may contribute to a dysfunctional 
mind–body state, through perpetuation of negative psycho-
logical states and associated body tension. Conversely, using 
awareness practices and defusing requirements may help 
individuals expand their awareness and foster a more bal-
anced, harmonious mind–body state, to more effectively 
deal with life’s challenges, such as cancer. MBB also 
addresses what might underpin resistances to clarity by pro-
posing a construct termed the “Identity System” or “I-Sys-
tem” in MBB teaching language. When the I-System gets 
activated (usually triggered by requirements) it generates a 
mind–body state that enhances self-centeredness and nega-
tive mental states, which can impede healthy functioning. 
Identifying when the I-System becomes activated may assist 
individuals in addressing and working to defuse their 
requirements, leading to a more harmonious outlook on life, 
and a better health status. MBB techniques are easy to learn 
and benefits may accrue rapidly. MBB was conducted by a 
licensed clinical social worker with MBB certification.
Because MBB provides dynamic instructions to help 
individuals develop greater awareness of their mental 
states and bodily sensations, some people may be tempted 
to think that MBB may be similar to biofeedback. 
However, biofeedback generally includes primarily elec-
tronic sensing devices to provide feedback information 
about various physiological signals, including brainwaves, 
muscle tone, heart rate, and pain, to assist in improving 
many different health and stress conditions, such as 
chronic pain, cardiac arrhythmias, hypertension, and anxi-
ety.67 Since biofeedback may be combined with interven-
tions such cognitive behavioral therapy, relaxation therapy, 
guided imagery, and psychological education,68 mind–
body interventions such as MBB may be used in conjunc-
tion with biofeedback therapy to potentially enhance its 
efficacy.
Adherence to Programs
Participants in all groups were asked to practice the tech-
niques they had learned and read the information provided 
on a daily basis. There was no time length specified for any 
of the groups to engage in home practice; nor was home 
practice standardized such that groups did not receive equal 
amounts of home practice. The practices that each group 
was encouraged to use at home are as follows: The SHE 
group was asked to review sleep topics that were provided 
to them in the form of handouts (indicated previously) and 
to implement what they had learned during the SHE ses-
sions both prior to and at bedtime. The MM group was 
encouraged to practice formal meditation techniques (such 
as the body scan and sitting and walking meditation) several 
times per week using the CDs to guide their meditation 
practice. Participants were also asked to practice moment-
to-moment breath awareness throughout the day (eg, while 
at a stop light, while on hold on the phone, when waiting in 
line, or during similar idle times). They were also encour-
aged, but not expected, to read pertinent sections of the 2 
books included in the course. The MBB group was asked to 
review the MBB concepts they had learned and keep refer-
ring to the handout they had received and practice the expe-
riential exercises (listening and paying attention to sounds, 
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feelings, sensations, etc) and mind–body mapping exercises 
during the day and in the evening before bedtime. 
Participants in each of the groups were not required to jour-
nal what they did, nor were they required to document how 
much time they spent on the various activities. In lieu of a 
journal, during sessions 2 and 3, participants in each group 
were asked to share what they had done each week to help 
improve their sleep and in their daily lives.
Outcome Measures
Salivary Oxytocin
Saliva collection. Participants were instructed to collect 
saliva prior to bed time (approximately10 pm) at all 3 col-
lection time points (Pre, Post, and Follow-up), according to 
a standardized procedure described previously.46 To facili-
tate compliance with collecting saliva, participants were 
instructed to write the time they collected saliva on the 
collecting tubes at each data collection time point. Saliva 
samples collected just before bedtime made it easier for 
participants to immediately freeze the sample, which is a 
critical step in the preservation of the OT peptide, which 
has a short half-life of 1 to 6 minutes.69 This collection 
time point was also selected, based on one study showing 
that OT increases throughout the day and peaks in the eve-
ning,70 supporting the evening collection to ensure higher 
OT levels. However, a more recent review article suggested 
that there was no consistent evidence for diurnal changes 
in OT.36 Participants collected saliva in their mouths for 1 
to 2 minutes and released the saliva into a prechilled small 
tube suspended in ice using the “passive drool” technique. 
If participants could not produce about 1 mL of saliva, they 
continued collecting for an additional 1 to 2 minutes. Par-
ticipants repeated this procedure with a second tube, and 
after collecting saliva, both tubes were immediately fro-
zen. In the instruction sheets provided, participants were 
urged to place sample tubes in a freezer as soon as they had 
completed saliva collection; however, we did not collect 
any measures of the extent of participant adherence to this 
protocol. Participants brought the frozen saliva collected at 
baseline to the first intervention session, and postinterven-
tion and follow-up collections to the Pain Research Cen-
ter (PRC) offices. Frozen saliva samples were stored at the 
PRC in a −20°C freezer. The entire batch of samples was 
then shipped to the University of North Carolina to conduct 
the sOT assays.
Salivary OT assay. The sOT enzyme-immunoabsorbance 
(EIA) method used to assay salivary OT in the present 
study was identical to that reported previously.46 Prior to 
conducting the OT assay, an extraction stage was included. 
Since there is some controversy about the accuracy of OT 
measurement in saliva due to concerns about the valid-
ity of OT assays of saliva samples, sample extraction is a 
recommended minimally necessary procedure for measur-
ing both plasma and salivary OT.71,72 Extraction gets rid 
of other molecules that could potentially interfere with OT 
measurement, and it additionally concentrates the sample 
(which is generally low) to ensure that OT concentrations 
are greater than the assay sensitivity level and remain in 
a more measurable assay range.69,72 Another problem with 
not conducting an extraction procedure is that unextracted 
OT concentrations are more than 2 orders of magnitude 
higher than extracted OT, in radioimmunoassays.46,69 While 
extraction removes other molecules, the accuracy of OT 
measurement could be affected by OT degradation prod-
ucts, as well as nonspecific reactants that are immunoreac-
tive and could contribute to final OT measurements; this 
applies to plasma OT as well as salivary and urinary OT, 
and as such, it is imperative to conduct appropriate vali-
dations for all types of samples.72 Some researchers even 
believe that saliva might not contain bioavailable OT.73 
Thus, caution is recommended since not enough research 
has been conducted to fully and satisfactorily characterize 
OT measurement in human body fluids, especially saliva, 
which is of great necessity in establishing the true function 
of OT found in peripheral tissues.72
Salivary OT levels were measured using the OT EIA 
(Enzo Life Sciences, Farmingdale, NY), in which the 
endogenous OT hormone competes for the OT antibody 
binding sites with added OT linked to alkaline phosphatase. 
After the overnight incubation at 41°C, the excess reagents 
were washed away and the bound OT phosphatase was 
incubated with substrate. After 1 hour, this enzyme reaction 
(which generates a yellow color) was stopped and the opti-
cal density (OD) was read on a Sunrise plate reader (Tecan, 
Research Triangle Park, NC) at 405 nm. The intensity of the 
color is inversely proportional to the concentration of OT in 
the sample. The hormone content (pg/mL) was determined 
by plotting the OD of each sample against a standard curve. 
After correcting for concentration produced by extraction, 
the lower limit of sensitivity was 1.5 pg/mL. The intra- and 
interassay variations for this assay were 4.8% and 8%, 
respectively, determined using a set control sample with 
known OT concentration on each plate and in each run. 
Enzo Life Sciences reports cross-reactivity for similar 
mammalian neuropeptides in sera at less than 0.001%.
Self-Report Measures
Sleep. Sleep was measured by the MOS-SS62, a vali-
dated 12-item scale evaluating sleep patterns over the past 
week and incorporating 6 subscales: (a) sleep disturbance, 
(b) sleep adequacy, (c) daytime somnolence, (d) snoring, (e) 
waking up short of breath with a headache, and (f) quantity 
of sleep. Two additional subscales evaluate composite sleep 
problems, namely, Sleep Problems Indexes I and II (SPI-I 
and SPI-II). SPI-II is a composite score reflecting sleep dis-
turbance, sleep adequacy, and somnolence, which was used 
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as both the eligibility inclusion measure and primary out-
come for the self-reported measures. Internal consistency 
for the current sample based on Cronbach’s α coefficient 
was .69.
Stress. The Perceived Stress Scale (PSS)74,75 measures 
the extent to which individuals perceive their lives to be 
unpredictable, uncontrollable, or overloaded. We used the 
10-item version, which has maximum reliability. Internal 
consistency for the current sample based on Cronbach’s α 
coefficient was .93.
Depression. The Center for Center for Epidemiological 
Studies–Depression Scale (CES-D)76 comprises 20 items 
and is one of the most common screening tests for the pres-
ence of depressive symptoms. Internal consistency for the 
current sample based on Cronbach’s α coefficient was .93.
Quality of life. The Functional Assessment of Cancer 
Therapy–General (FACT-G)77 is a 27-item cancer-related 
QOL measure, which is divided into 4 primary QOL 
domains: Physical Well-Being, Social/Family Well-Being, 
Emotional Well-Being, and Functional Well-Being. It is 
appropriate for use with patients with any form of cancer, 
and it has been used to evaluate cancer-related QOL in 
many studies.78-82 Internal consistency for the current sam-
ple based on Cronbach’s α coefficient was .92.
Well-being. The World Health Organization Well-Being 
Index (WBI)83 is a 5-item index covering positive and nega-
tive aspects of emotional functioning. Internal consistency 
for the current sample based on Cronbach’s α coefficient 
was .90.
Mindfulness. The Five-Facet Mindfulness Question-
naire (FFMQ)84 includes 39 items and assesses 5 dis-
tinct, interpretable facets of mindfulness: (a) observing, 
(b) describing, (c) acting with awareness, (d) nonjudging 
of inner experience, and (e) nonreactivity to inner expe-
rience. We evaluated the effects of the interventions on 
mindfulness using the total mindfulness score. Internal 
consistency for the current sample based on Cronbach’s α 
coefficient was .93.
Self-compassion. The Self-Compassion Scale (SCS)85 is 
a 26-item used to measure self-compassion, an emotionally 
positive attitude thought to protect against the negative con-
sequences of self-judgment, isolation, and rumination. The 
total self-compassion score was computed and used as the 
raw data. Internal consistency for the current sample based 
on Cronbach’s α coefficient was .96.
Participants completed these self-reported outcome mea-
sures at approximately the same 3 collection time points 
(Pre, Post, and Follow-up) as the saliva samples.
Statistical Analysis
All data analyses were conducted with SPSS software, 
Version 18.0 (IBM, Chicago, IL).
Baseline sOT levels were initially evaluated to deter-
mine if there were any differences in sOT as an effect of 
sex, using a t test. We also evaluated whether baseline 
sOT levels varied as a function of (a) age and (b) baseline 
self-reported outcome measures, including sleep prob-
lems index, depression, perceived stress, well-being, 
FACT-G, mindfulness, and self-compassion, using corre-
lation analysis (Spearman’s ρ). We additionally deter-
mined intra-individual reliability of sOT levels over the 
course of the study (Pre, Post, and Follow-up) using cor-
relation analysis (Spearman’s ρ).
Salivary Oxytocin. The analysis evaluated the effects of the 
mind–body programs (MM, MBB) compared with that of 
SHE, on sOT levels at postintervention (comprising Post 
and Follow-up). The sOT data were not normally distrib-
uted and consequently were log-transformed (logOT) 
prior to analysis. We used a mixed effects model analysis 
of variance (ANOVA) to estimate intervention effects as 
the change in sOT at postintervention (subtracted from 
baseline) for each mind–body intervention versus SHE. 
We additionally evaluated sOT change from baseline 
within each of the mind–body interventions and SHE 
independently. The mixed effects ANOVA specified a fac-
torial design with Treatment and Period as fixed effects, 
and an unrestricted covariance matrix. The maximum like-
lihood estimates from the mixed model are “intent-to-
treat,” retaining all observations with no imputation of 
missing values. In the present study, randomization pro-
duced significantly different baseline (Pre) distributions 
across groups (see Results). With smaller samples and 
baseline imbalance, some degree of regression artifact is 
inevitable when evaluating change. To minimize this 
impact, we also conducted comparable analysis of covari-
ance (ANCOVA) analyses, adjusting for baseline observa-
tions. The estimated adjusted effect magnitudes were 
broadly similar to those from the change analyses, with 
only the MBB sample showing an increase in the adjusted 
mean log(sOT) from baseline.
Sleep and Other Self-Report Outcome Measures. The analy-
ses determined the effects of the mind–body programs 
(MM, MBB) compared with that of SHE at postassessment 
and follow-up, for sleep (MOS-SS: SPI-II), perceived 
stress (PSS), depression (CES-D), well-being (WBI), QOL 
(FACT-G), mindfulness (FFMQ), and self-compassion 
(SCS), in the subset of cancer survivors from the main 
study,61 who provided saliva samples for sOT evaluation. 
Statistical analyses were mixed effects model ANOVAs, 
and intervention effects were estimated as each outcome 
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measure’s change subtracted from baseline for each mind–
body intervention versus SHE. Additional analysis exam-
ined change in outcome measure within each mind–body 
intervention and SHE, independently. The mixed effects 
ANOVAs used a factorial design with Treatment and 
Period as fixed effects, and an unrestricted covariance 
matrix. The maximum likelihood estimates from the mixed 
model are “intent-to-treat,” retaining all observations with 
no imputation of missing values.
Results
Demographics and Clinical Characteristics
Table 1 presents age, the number of subjects identified by 
sex, and clinical characteristics in this subset of cancer sur-
vivors evaluated for sOT. Groups were fairly well balanced 
and did not differ substantially in age and sex, although 
there were some differences in clinical characteristics, such 
as fewer breast cancer survivors in the MBB group (n = 2) 
than in either the SHE (n = 5) or MM (n = 7) group.
Baseline sOT Levels in Cancer Survivors
Mean sOT levels at baseline (Pre) in females (mean, 5.52; 
SD, 3.89, n = 21) were higher than those in males (4.37; 
2.46, n = 9), but did not differ statistically (t test: t = .82, 
P = .42). Consequently, for the sOT analyses we pooled 
female and male sOT raw data.
Relationship Between Baseline sOT  
Levels and Age
The correlation between baseline sOT levels and age (29-74 
years old) was not statistically significant (r = −.13; P = .485).
Relationship Between Baseline sOT Levels and 
Baseline Self-Reported Outcome Measures
Table 2 provides correlations between baseline sOT levels 
and baseline self-report measures. Salivary OT was not sig-
nificantly correlated with any self-report measure. However, 
correlations between sOT and several of the self-report 
measures were in the predicted direction: a negative asso-
ciation of sOT with sleep and depression, and a positive 
association of sOT with QOL and well-being.
Reliability of OT Measures
Salivary OT levels across the 3 assessments periods (Pre, 
Post, and Follow-up) were significantly correlated between 
Pre and Post (r = .61; P = .001) and Post versus Follow-up 
(r = .68; P = .001), while Pre versus Follow-up were mod-
erately associated (r = .36; P = .092).
Intervention Effects on sOT
Table 3 displays raw mean sOT levels for each intervention 
across the 3 time points. At Pre (baseline), sOT levels varied 
Table 1. Baseline Demographics and Clinical Characteristics for Participants Sampled for sOT in Each Intervention Group.
SHE MBB MM
Age (years) 48.3 (11.4)a 55.9 (11.9) 50.1 (9.52)
Sex
 Females 6 6 9
 Males 3 4 2
 Total 9 10 11
Clinical characteristics
 a. Previous diagnosis of  
 Breast cancer 5 2 7
 Other cancersb 4 8 4
 First cancer diagnosis (median years) 3 yr 4 mo 2 yr 10 mo 3 yr 1 mo
 Insomnia diagnosis 3 4 3
 Clinical depression 3 4 1
 b. Self-reported medications/supplements:  
 Sleep medications 2 1 3
 Antidepressants 4 4 4
 Any prescription medications 9 8 11
 Any supplements/herbal remedies 7 10 11
Abbreviations: sOT, salivary oxytocin; SHE, sleep hygiene education; MBB, mind–body bridging; MM, mindfulness meditation; CNS, central nervous 
system.
aStandard deviation in parentheses.
bType of cancer, including ovarian, endometrial, testicular, prostate, lung, melanoma, ependymona, leukemia, kidney, lymphomas (non-Hodgkin’s, CNS), 
skin carcinoma, brain, thyroid, peritoneal.
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significantly among the 3 treatment groups (one-way 
ANOVA: F = 7.05, P = .003), with higher sOT levels in the 
SHE group compared with those in MM and MBB. For this 
reason, we analyzed change from baseline sOT levels at pos-
tintervention (Post and Follow-up) to determine whether sOT 
levels differed in each mind–body intervention compared 
with that in SHE. Figure 1 presents change from baseline log-
transformed sOT levels at Post and Follow-up for each of the 
3 interventions and shows that sOT levels were significantly 
greater at postintervention in MBB compared with those in 
SHE (t = 2.05, P = .049), but they did not differ between SHE 
and MM (t = .53, P = .60). Cohen’s (d) effect size for the com-
parison between MBB and SHE was .82. (Cohen’s d was cal-
culated by subtracting the change from baseline for Post and 
Follow-up sOT levels of MBB and SHE, divided by their 
pooled standard deviations.) This large effect size for Cohen’s 
d should be considered with caution, since it is based on sOT 
levels decreasing in SHE at Post and Follow-up, and sOT lev-
els increasing in MBB at these time points. Thus, this finding 
should be further evaluated and replicated in a larger study 
designed to evaluate changes in sOT in cancer survivors.
As seen in Figure 1, for within-group comparisons, sOT 
levels increased from baseline only in the MBB group (ie, 
changes from baseline sOT levels are positive) at postinter-
vention (comprising Post and Follow-up), although these 
increases were not significant (t = 1.46, P = .156). In the other 
interventions, sOT levels in SHE showed a nonsignificant 
decline at postintervention (ie, change from baseline sOT 
levels was negative), while sOT levels in MM did not change 
significantly (SHE: t = 1.46, P = .158; MM: t = .85, P = .405).
Intervention Effects on Self-Reported Outcome 
Measures
For the subset of cancer survivors from the main study who 
provided saliva samples for sOT evaluation, we assessed 
the effects of the interventions on the various self-report 
measures. Table 3 presents raw mean scores for sleep 
(MOS-SS), depression (CES-D), quality of life (FACT-G), 
well-being (WBI), perceived stress (PSS), mindfulness 
(FFMQ), and self-compassion (SCS), for each intervention 
at Pre, Post, and Follow-up. Statistical analyses for each of 
the self-reported outcome measures evaluated in the present 
study are presented below.
For the sleep measure, the analysis revealed that SPI-II 
change scores at Post and Follow-up were significantly 
lower in MBB (t = 2.63, P = .013) and MM (t = 2.56, P = 
.016) compared with those in SHE, indicating greater 
improvements in sleep in the mind–body interventions than 
in the control group. Within-group analyses indicated that 
SPI-II scores were lower at Post and Follow-up compared 
with those at Pre, in MBB (t = 5.40, P < .001) and MM (t = 
5.53, P < .001), but not in SHE (t = 1.49, P = .146), suggest-
ing that sleep improved to a greater extent in the MM and 
MBB groups, but not in SHE.
For the other self-reported outcome measures, the statis-
tical analyses revealed that changes from baseline scores at 
Post and Follow-up in MBB were greater compared with 
those in SHE, for mindfulness (FFMQ; t = 2.02, P = .050) 
and self-compassion (SCS; t = 2.07, P = .048).
Based on the CESD scale, self-reported depression 
decreased in MBB more so than SHE, but the difference 
between the 2 groups (t = 1.88, P = .072) did not reach sig-
nificance. As indicated in Table 3, CESD scores were fairly 
high at baseline and above the cutoff of 16, indicative of 
being at risk for clinical depression.76 Specifically, the raw 
data indicate that in each of the 3 groups approximately two 
thirds (SHE, 6/9 = 67%; MBB, 6/10 = 60%; MM, 8/11 = 
73%) of participants were above the cutoff at baseline.
Statistical analyses of the other outcomes measures, 
including perceived stress, FACT-G, and well-being, did 
not differ for the 2 mind–body therapies compared with that 
of SHE at Post and Follow-up.
Discussion
In this exploratory study of a subset analysis of cancer sur-
vivors with self-reported sleep disturbance investigated pre-
viously in the main study,61 we evaluated the feasibility and 
acceptability of measuring sOT, as well as the influences of 
sleep-focused mind–body interventions, MBB and MM, on 
sOT levels. We also investigated sOT as a potential biologi-
cal marker of improved QOL and well-being in cancer sur-
vivors. We found that within-individual sOT reliability was 
high for comparisons between baseline and Post, and Post 
and Follow-up, and moderate between baseline and 
Follow-up. Furthermore, baseline sOT levels did not differ 
between females and males and were not correlated with 
age. While correlations between sOT and self-report mea-
sures were weak, several of the associations were in the 
Table 2. Relationships at Baseline Between Salivary Oxytocin 
Levels and Self-Reported Outcome Measures.
Correlation With sOT Levels
 Spearman’s ρ Sig. (2-tailed)




Perceived Stress −.063 .740
Mindfulness −.004 .983
Self-compassion −.039 .840
Abbreviations: sOT, salivary oxytocin; FACT-G, Functional Assessment 
of Cancer Therapy–General.
Value in bold reflects a trend in the association between the self-
reported outcome measure and sOT levels.
Lipschitz et al 375
predicted direction, namely, sOT was negatively associated 
with sleep and depression and positively associated with 
QOL and well-being. Baseline subtracted sOT levels at Post 
and Follow-up in MBB participants were significantly 
greater than those in the SHE control. In these cancer survi-
vors who provided saliva samples for sOT measurement, 
sleep problems change scores decreased at Post and 
Follow-up in MBB and MM compared with those in SHE, 
while significant increases in mindfulness and self-compas-
sion at Post and Follow-up were observed in the MBB 
group compared with those in the SHE group, indicating 
that in this subset group, results were similar to that of the 
main study.61 The findings in this exploratory study suggest 
that sOT could be a reliable biological measure over time, 
and thus may be useful in future studies examining the 
effects of mind–body interventions on health outcomes in 
cancer survivors. However, a more strongly powered study 
is required to conclusively determine whether mind–body 
interventions may influence changes in sOT levels in cancer 
survivors.
In the present study, we observed that within-individual 
sOT levels in cancer survivors were fairly consistent across 
the 3 months of data collection (from baseline to the 2-month 
follow-up assessment), indicating reliability of sOT levels 
over time. While there are no other studies conducted on 
salivary OT to compare with the current study, plasma OT 
concentrations are highly stable within individuals when 
sampled over a 6-month period.86 This intra-individual reli-
ability of both plasma OT and sOT levels may be important 
when assessing possible associations between the endoge-
nous OT system and various health-related states, including 
well-being and QOL. This type of assessment would neces-
sarily require more frequent sampling periods for OT mea-
surement, hence the benefits of sampling OT from saliva.
At baseline, while sOT and self-report measures were 
weakly correlated in a number of self-report measures, the 
correlations went in the predicted direction: sOT was posi-
tively associated with well-being and QOL and negatively 
associated with sleep disturbance and depression. Other 
studies have similarly failed to identify compelling links 
between biological measures and psychological outcome 
measures (see Carlson et al87). This lack of correlation 
between physiological and psychological measures sug-
gests that more effort is needed in designing studies that can 
capture the complexities and potential variability in both 
types of measures. One approach is concurrent and repeated 
Table 3. Raw Means (and SDs) of Salivary Oxytocin Levels and the Self-Reported Outcome Measures Evaluated in This Study Across 
the 3 Interventions, at Baseline (Pre), Postintervention (Post), and Follow-up.
Period SHE MBB MM P Value
Salivary oxytocin 
(pg/mL)
Pre 8.15 (4.09) 3.38 (1.54) 4.37 (2.91) MBB vs SHE: .049
Post 7.02 (5.20) 4.74 (2.82) 3.56 (2.48)
Follow-up 5.66 (2.70) 4.27 (1.25) 4.24 (2.82)
Sleep Problems 
Index-II
Pre 47.90 (18.57) 57.89 (13.74) 57.93 (13.49) MBB vs SHE: .013; 
MM vs SHE: .016Post 42.28 (12.30) 32.04 (17.25) 36.57 (15.19)
Follow-up 40.19 (18.40) 36.67 (20.76) 31.67 (12.05)
Depression Pre 20.11 (12.76) 23.00 (12.81) 19.73 (10.81)  
Post 15.22 (11.10) 13.56 (11.34) 15.82 (6.74)  
Follow-up 16.17 (10.23) 13.29 (12.19) 13.89 (8.67)  
Well-being Pre 11.33 (3.17) 10.60 (1.54) 12.73 (2.91)  
Post 13.67 (3.10) 15.11 (2.82) 14.64 (2.48)  
Follow-up 17.00 (2.70) 16.43 (1.25) 16.11 (2.82)  
FACT-G Baseline 73.89 (24.24) 67.42 (15.96) 70.48 (17.04)  
Post 74.78 (17.91) 72.44 (21.59) 75.23 (14.23)  
Follow-up 80.33 (14.62) 73.26 (19.97) 78.65 (16.92)  
Perceived stress Pre 15.56 (6.93) 19.10 (5.38) 19.82 (8.18)  
Post 13.78 (6.94) 15.67 (4.09) 17.82 (4.75)  
Follow-up 12.50 (7.09) 13.30 (5.12) 14.67 (4.36)  
Mindfulness Pre 134.78 (21.52) 128.60 (17.17) 125.27 (24.57) MBB vs SHE: .050
Post 129.67 (26.29) 141.67 (15.98) 135.18 (22.31)
Follow-up 146.67 (18.62) 144.57 (13.35) 137.22 (22.48)
Self-compassion Pre 91.11(23.57) 77.00 (22.79) 87.64 (19.44) MBB vs SHE: .048
Post 88.33 (21.32) 83.00 (19.10) 87.91 (13.95)
Follow-up 99.67 (19.82) 87.57 (27.28) 94.11 (15.59)
Abbreviations: SHE, sleep hygiene education; MBB, mind–body bridging; MM, mindfulness meditation; FACT-G, Functional Assessment of Cancer 
Therapy–General.
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collection time points and identifying appropriate self-
report measures that are indicative of state effects.
To our knowledge, the present study is the first to exam-
ine the influence of mind–body interventions on sOT levels 
in cancer survivors. Previous studies examining the poten-
tial role of endogenous OT in health and well-being and its 
associations with positive health states are few, and they 
have been confined to tactile interventions such as gentle or 
warm touch46,88 and massage therapy.37,44,45,47,48 Thus, while 
more work is necessary to fill the gaps in the area of mind–
body interventions and their relationships with OT, results 
of these studies could provide an important understanding 
of potential OT mechanisms that are mediated by mind–
body interventions in improving cancer survivors’ health 
outcomes, including sleep.
There appears to be a lack of studies investigating sali-
vary or plasma OT levels in cancer patients at different 
stages of cancer and treatment, or in cancer survivors, and 
as related to cancer prognosis. In this regard, the relation-
ship between OT and cancer could be an important research 
avenue, since understanding the role that OT plays in can-
cer progression and survivorship might provide important 
information promoting the incorporation of OT as a screen-
ing tool to obtain a more comprehensive understanding of 
a cancer patient or survivor’s health status. Furthermore, 
OT could serve as a potentially important biomarker in 
assessing various aspects of a cancer patient’s QOL and 
well-being to help better understand how OT might 
enhance cancer prognosis.
As is the case in many endocrine studies in which sub-
stantial variability in hormone levels is often observed, 
large variations in sOT levels were also evident in this 
study, in which certain participants exhibited consistently 
higher sOT levels. In addition, large differences in sOT lev-
els were seen at baseline, in which mean sOT levels were 
significantly higher in SHE compared to those in MBB and 
MM. While we could not ascertain what accounted for such 
divergent sOT levels, one factor may have been the differ-
ent cancer diagnoses and treatments in this population, 
although our study excluded individuals with a current can-
cer diagnosis or having received treatment such as radia-
tion, surgery, or chemotherapy within the past 3 months. It 
is also possible that differences in baseline sOT levels could 
be related to participants exhibiting different psychological 
states, for example, SHE comprising individuals with 
higher levels of perceived stress or depression than the 
other interventions. While there was a lack of significant 
correlations at baseline between sOT and the self-report 
measures across all individuals, the small size of each inter-
vention group precluded identifying meaningful relation-
ships between sOT levels and psychological variables 
within each group. As a further alternative, since OT is 
strongly implicated in prosocial behavior, sOT levels might 
have been influenced by participants’ living environment: 
Figure 1. Comparisons among interventions (SHE, MBB, and MM) of mean (with SEM) change from baseline sOT levels at 
postintervention (Post) and 2 months later (Follow-up).
Change from baseline sOT levels at Post and Follow-up were greater in MBB compared with those in the SHE group (P = .049). Please note that the 
standard errors are included for descriptive reference and do not reflect the statistical tests that were conducted.
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whether they have a spouse or partner, reside with another 
person or live alone, and the type of social support provided 
to these cancer survivors. In a future study, these factors 
would need to be assessed to examine the influence of a 
person’s social environment on sOT levels.
Recent studies have demonstrated that OT may moderate 
the relationship between psychosocial indices and health 
outcomes.32 Similarly, it would be interesting to determine 
if sOT in the current study could moderate the relationship 
between intervention effects on sleep and psychosocial 
states such as perceived stress and depression. Unfortunately, 
sample sizes within interventions were too small to conduct 
this type of analysis.
One of the limitations of this study was that only one 
saliva sample was collected at each time point. As has been 
generally suggested for measuring salivary hormones, it 
would be more advantageous to collect 2 to 3 saliva sam-
ples over at least 2 consecutive days, to increase intra-indi-
vidual reliability of sOT measures, as has been suggested 
for cortisol.89 Also, it is important to ensure that collection 
of saliva samples and self-report measures are collected as 
close to each other as possible. Another concern is the issue 
of recall for the self-report measures. For example, partici-
pants collected saliva samples in the evening before going 
to bed, and the sleep questionnaire ascertained sleep perfor-
mance over the previous week. A better strategy would have 
been to collect saliva samples around the same time that a 
sleep diary was completed for the previous night’s sleep. 
Thus, having 2 to 3 saliva samples and concomitant sleep 
diary entries at each time point would have made it possible 
to collect sufficiently rich and informative data on complex 
relationships between this biomarker and other relevant 
variables.
Other limitations included that each group was not pro-
vided with an explicit task of documenting how long they 
practiced their respective intervention’s techniques, nor was 
the amount of practice among the 3 groups standardized for 
them to engage in approximately equal amounts of home 
practice. One limitation concerning saliva collection was 
that we did not measure participant adherence to the saliva 
collection protocol.
Assays evaluating salivary OT levels have been ques-
tioned for their reliability,71,72 since it has been shown that 
sOT assays correlate weakly with EIA-based estimates of 
OT in unextracted plasma, with low shared variance 
between salivary and plasma measures (between 17% and 
35%).13,47,69 For this reason, we included an extraction tech-
nique, which has demonstrated a better validation profile.69 
The case for measuring salivary OT is compelling given 
some of the advantages of collecting saliva samples. Under 
certain circumstances, sOT may be the only possible mea-
sure that can be obtained, for example, when participants do 
not wish to have their blood drawn, or when the ability to 
collect blood is impractical, such as in the home. In 
addition, setting up and collecting blood draws in group 
intervention studies can be a laborious endeavor. The 
strengths and weaknesses of the sOT sampling method are 
not different than for other commonly measured and vali-
dated biomarkers such as salivary cortisol.69 In support of 
salivary OT as a potentially valid physiological measure, 
intranasal OT studies have demonstrated an association 
between increases in sOT and behavioral and neural 
changes.90 More research is necessary to further validate 
sOT and characterize sOT levels and patterns of release.
We acknowledge that the finding of significant differ-
ences between MBB and SHE in change from baseline sOT 
levels at Post and Follow-up should be considered prelimi-
nary and may be due in part to initial baseline differences 
among the groups, in which SHE started out with higher 
sOT levels than either those in MBB or MM. Small sample 
sizes are particularly susceptible to baseline imbalance. 
Thus, we cannot conclusively state that the differences in 
sOT levels between the 2 groups were due to intervention 
effects. Future studies examining the effects of mind–body 
interventions on sOT levels should include larger sample 
sizes to more strongly power the study for these analyses. A 
larger sample size would also reduce the likelihood of base-
line imbalance of sOT levels among groups.
In conclusion, while this exploratory study has a number 
of limitations, it suggests that sOT may be a reliable bio-
logical measure over time and that it may be useful in evalu-
ating the effects of mind–body interventions in cancer 
survivors. Finally, one of the goals of this study was to 
determine an effect size mediated by mind–body interven-
tions for designing a more definitive randomized controlled 
trial, to better understand the role of OT in facilitating health 
and well-being in cancer survivors.
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